Association of interleukin-6 (-174 G/C) polymorphism with the prostate cancer risk: A meta-analysis

Yang, Mingyuan; Li, Chao; Li, Ming

doi:10.3892/br.2014.300

Cited by 14 publications

(11 citation statements)

References 42 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IL-6 can induce phenotypic change in cells in colon tumors, which leads to drug resistance. It can also stimulate carcinogen metabolism in situ, leading to DNA damage and enhanced tumor invasiveness (Meenagh et al, 2002;Yang et al, 2014).…”

Section: Discussionmentioning

confidence: 99%

Correlation analysis between an IL-6 genetic polymorphism and non-small cell lung cancer prognosis

Zhao

Tian

2016

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Interleukin-6 (IL-6) is a multifunctional cytokine that is involved in tumor cell proliferation, apoptosis, and differentiation. The purpose of this study was to evaluate the impact of the single nucleotide polymorphism (SNP) -174G/C in IL-6 on the prognosis and pain tolerance of non-small cell lung cancer (NSCLC) patients. DNA was extracted from the peripheral blood of 434 patients with NSCLC, which was diagnosed by cytology or histology. Polymerase chain reaction-restriction fragment length polymorphism was used to detect the IL-6 -174G/C genotypes and their correlation with survival was analyzed. The IL-6 -174G/C genotypes were high IL-6 production type (G carriers -GG or GC genotypes) and low IL-6 production type (CC genotype). The correlation between the IL-6 SNP and pain level/analgesic use was also analyzed. Survival analysis showed that patients carrying the G allele (CG/GG) had a shorter survival time than patients with the CC genotype. The -174G/C SNP is in the promoter region of the IL-6 gene and may be associated with changes in gene transcription and serum cytokine levels. Presence of the IL-6 -174G/C SNP is significantly correlated with morphine equivalent daily dose. Patients with the CC genotype needed a higher opioid dose than patients with the GG or GC genotypes. In conclusion, we found that the IL-6 -174G/C SNP is closely related to survival, analgesic use and pain tolerance in NSCLC patients. However, it is necessary to further validate the results with a larger patient cohort and elucidate the mechanisms of this SNP. Link to retraction noticed R E T R A C T I O N

show abstract

Section: Discussionmentioning

confidence: 99%

Correlation analysis between an IL-6 genetic polymorphism and non-small cell lung cancer prognosis

Zhao

Tian

2016

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…Therefore, it is reasonable to assume that sequence variants in genes coding proinflammatory and anti-inflammatory cytokines influence PCa risk, since cytokine gene polymorphisms may lead to an altered production of cytokines (Hollegaard and Bidwell, 2006). Meta-analyses have been performed about the association between polymorphisms of proinflammatory [IL-6, IL-8, and tumor necrosis factor-α (TNF-α)] Ma et al, 2014;Yang et al, 2014) and anti-inflammatory (IL-10) (Yu et al, 2013) cytokines and PCa risk. Another proinflammatory cytokine, IL-1, though important in inflammation, was not fully examined about its role in the development of PCa.…”

Section: Discussionmentioning

confidence: 99%

“…IL-6 variants were found to have little association with PCa risk (Yang et al, 2014). Though several studies reported no association between IL-8-251 polymorphism and PCa risk (Yang et al, 2006), a reduction in risk was observed among carriers of -251A .…”

Section: Genetic Polymorphism Of Interleukin-1a (Il-1a) Il-1b and Imentioning

confidence: 95%

Genetic Polymorphism of Interleukin-1A (IL-1A), IL-1B, and IL-1 Receptor Antagonist (IL-1RN) and Prostate Cancer Risk

Xu¹,

Ding²,

Jiang³

2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Therefore, this cytokine could contribute to the initiation, development, and metastasis of prostate cancer. Several studies have shown an association between IL-6 gene polymorphisms and the risk of prostate cancer, but the results are inconclusive (Magalhães et al, 2013;Mandić et al, 2013;Mandal et al, 2014;Yang et al, 2014). In this study, we investigated the role of two functional polymorphisms, IL-6-174G>C (rs1800795) and IL-6-572C>G (rs1800796), in the development of prostate cancer.…”

Section: Introductionmentioning

confidence: 94%

Role of interleukin-6 gene polymorphisms in the development of prostate cancer

Chen¹,

Gong²,

Quan³

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We investigated the role of two functional polymorphisms, IL-6-174G>C (rs1800795) and IL-6-572C>G (rs1800796), in the development of prostate cancer. A total of 212 consecutive primary prostate cancer patients and 236 control subjects were recruited between May 2012 and May 2014. The IL-6-174G>C (rs1800795) and IL-6-572C>G (rs1800796) polymorphisms were assessed by polymerase chain reaction-restriction fragment length polymorphism. The genotype distributions of IL-6-174G>C (rs1800795) and IL-6-572C>G (rs1800796) met the HardyWeinberg equilibrium in the controls. Unconditional logistic regression analyses showed that the GG genotype of IL-6-572C>G (rs1800796) was associated with an elevated risk of prostate cancer compared with the CC genotype, and the OR (95%CI) for the GG genotype was 2.06 (1.11-3.87). In conclusion, we suggest that the IL-6-572C>G (rs1800796) gene polymorphism influences the development of prostate cancer.

show abstract

Association of interleukin-6 (-174 G/C) polymorphism with the prostate cancer risk: A meta-analysis

Cited by 14 publications

References 42 publications

Correlation analysis between an IL-6 genetic polymorphism and non-small cell lung cancer prognosis

Correlation analysis between an IL-6 genetic polymorphism and non-small cell lung cancer prognosis

Genetic Polymorphism of Interleukin-1A (IL-1A), IL-1B, and IL-1 Receptor Antagonist (IL-1RN) and Prostate Cancer Risk

Role of interleukin-6 gene polymorphisms in the development of prostate cancer

Contact Info

Product

Resources

About